These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20347591)

  • 1. The discovery and structure-activity relationships of pyrano[3,4-b]indole based inhibitors of hepatitis C virus NS5B polymerase.
    LaPorte MG; Draper TL; Miller LE; Blackledge CW; Leister LK; Amparo E; Hussey AR; Young DC; Chunduru SK; Benetatos CA; Rhodes G; Gopalsamy A; Herbertz T; Burns CJ; Condon SM
    Bioorg Med Chem Lett; 2010 May; 20(9):2968-73. PubMed ID: 20347591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The discovery and structure-activity relationships of pyrano[3,4-b]indole-based inhibitors of hepatitis C virus NS5B polymerase.
    Jackson RW; LaPorte MG; Herbertz T; Draper TL; Gaboury JA; Rippin SR; Patel R; Chunduru SK; Benetatos CA; Young DC; Burns CJ; Condon SM
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3227-31. PubMed ID: 21550237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The discovery of pyrano[3,4-b]indole-based allosteric inhibitors of HCV NS5B polymerase with in vivo activity.
    Laporte MG; Jackson RW; Draper TL; Gaboury JA; Galie K; Herbertz T; Hussey AR; Rippin SR; Benetatos CA; Chunduru SK; Christensen JS; Coburn GA; Rizzo CJ; Rhodes G; O'Connell J; Howe AY; Mansour TS; Collett MS; Pevear DC; Young DC; Gao T; Tyrrell DL; Kneteman NM; Burns CJ; Condon SM
    ChemMedChem; 2008 Oct; 3(10):1508-15. PubMed ID: 18729128
    [No Abstract]   [Full Text] [Related]  

  • 4. Discovery of pyrano[3,4-b]indoles as potent and selective HCV NS5B polymerase inhibitors.
    Gopalsamy A; Lim K; Ciszewski G; Park K; Ellingboe JW; Bloom J; Insaf S; Upeslacis J; Mansour TS; Krishnamurthy G; Damarla M; Pyatski Y; Ho D; Howe AY; Orlowski M; Feld B; O'Connell J
    J Med Chem; 2004 Dec; 47(26):6603-8. PubMed ID: 15588095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quinolones as HCV NS5B polymerase inhibitors.
    Kumar DV; Rai R; Brameld KA; Somoza JR; Rajagopalan R; Janc JW; Xia YM; Ton TL; Shaghafi MB; Hu H; Lehoux I; To N; Young WB; Green MJ
    Bioorg Med Chem Lett; 2011 Jan; 21(1):82-7. PubMed ID: 21145235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of HCV NS5B thumb site I inhibitors: core-refining from benzimidazole to indole scaffold.
    Zhao F; Liu N; Zhan P; Jiang X; Liu X
    Eur J Med Chem; 2015 Apr; 94():218-28. PubMed ID: 25768704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. I. Novel HCV NS5B polymerase inhibitors: discovery of indole 2-carboxylic acids with C3-heterocycles.
    Anilkumar GN; Lesburg CA; Selyutin O; Rosenblum SB; Zeng Q; Jiang Y; Chan TY; Pu H; Vaccaro H; Wang L; Bennett F; Chen KX; Duca J; Gavalas S; Huang Y; Pinto P; Sannigrahi M; Velazquez F; Venkatraman S; Vibulbhan B; Agrawal S; Butkiewicz N; Feld B; Ferrari E; He Z; Jiang CK; Palermo RE; McMonagle P; Huang HC; Shih NY; Njoroge G; Kozlowski JA
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5336-41. PubMed ID: 21840715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Finger-loop inhibitors of the HCV NS5b polymerase. Part 1: Discovery and optimization of novel 1,6- and 2,6-macrocyclic indole series.
    McGowan D; Vendeville S; Lin TI; Tahri A; Hu L; Cummings MD; Amssoms K; Berke JM; Canard M; Cleiren E; Dehertogh P; Last S; Fransen E; Van Der Helm E; Van den Steen I; Vijgen L; Rouan MC; Fanning G; Nyanguile O; Van Emelen K; Simmen K; Raboisson P
    Bioorg Med Chem Lett; 2012 Jul; 22(13):4431-6. PubMed ID: 22542193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a novel series of non-nucleoside thumb pocket 2 HCV NS5B polymerase inhibitors.
    Stammers TA; Coulombe R; Rancourt J; Thavonekham B; Fazal G; Goulet S; Jakalian A; Wernic D; Tsantrizos Y; Poupart MA; Bös M; McKercher G; Thauvette L; Kukolj G; Beaulieu PL
    Bioorg Med Chem Lett; 2013 May; 23(9):2585-9. PubMed ID: 23545108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allosteric inhibitors of hepatitis C virus NS5B polymerase thumb domain site II: structure-based design and synthesis of new templates.
    Malancona S; Donghi M; Ferrara M; Martin Hernando JI; Pompei M; Pesci S; Ontoria JM; Koch U; Rowley M; Summa V
    Bioorg Med Chem; 2010 Apr; 18(8):2836-48. PubMed ID: 20363140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based virtual screening, synthesis and SAR of novel inhibitors of hepatitis C virus NS5B polymerase.
    Talele TT; Arora P; Kulkarni SS; Patel MR; Singh S; Chudayeu M; Kaushik-Basu N
    Bioorg Med Chem; 2010 Jul; 18(13):4630-8. PubMed ID: 20627595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-nucleoside inhibitors of HCV NS5B polymerase. Part 1: Synthetic and computational exploration of the binding modes of benzothiadiazine and 1,4-benzothiazine HCV NS5b polymerase inhibitors.
    Hendricks RT; Fell JB; Blake JF; Fischer JP; Robinson JE; Spencer SR; Stengel PJ; Bernacki AL; Leveque VJ; Le Pogam S; Rajyaguru S; Najera I; Josey JA; Harris JR; Swallow S
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3637-41. PubMed ID: 19447623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclic amide bioisosterism: strategic application to the design and synthesis of HCV NS5B polymerase inhibitors.
    Yang H; Hendricks RT; Arora N; Nitzan D; Yee C; Lucas MC; Yang Y; Fung A; Rajyaguru S; Harris SF; Leveque VJ; Hang JQ; Pogam SL; Reuter D; Tavares GA
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4614-9. PubMed ID: 20584604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyridobenzothiazole derivatives as new chemotype targeting the HCV NS5B polymerase.
    Manfroni G; Meschini F; Barreca ML; Leyssen P; Samuele A; Iraci N; Sabatini S; Massari S; Maga G; Neyts J; Cecchetti V
    Bioorg Med Chem; 2012 Jan; 20(2):866-76. PubMed ID: 22197397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5,5'- and 6,6'-dialkyl-5,6-dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase.
    Ellis DA; Blazel JK; Tran CV; Ruebsam F; Murphy DE; Li LS; Zhao J; Zhou Y; McGuire HM; Xiang AX; Webber SE; Zhao Q; Han Q; Kissinger CR; Lardy M; Gobbi A; Showalter RE; Shah AM; Tsan M; Patel RA; LeBrun LA; Kamran R; Bartkowski DM; Nolan TG; Norris DA; Sergeeva MV; Kirkovsky L
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6047-52. PubMed ID: 19796938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel thiazolones as HCV NS5B polymerase allosteric inhibitors: Further designs, SAR, and X-ray complex structure.
    Yan S; Larson G; Wu JZ; Appleby T; Ding Y; Hamatake R; Hong Z; Yao N
    Bioorg Med Chem Lett; 2007 Jan; 17(1):63-7. PubMed ID: 17049849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase.
    Gentles RG; Ding M; Bender JA; Bergstrom CP; Grant-Young K; Hewawasam P; Hudyma T; Martin S; Nickel A; Regueiro-Ren A; Tu Y; Yang Z; Yeung KS; Zheng X; Chao S; Sun JH; Beno BR; Camac DM; Chang CH; Gao M; Morin PE; Sheriff S; Tredup J; Wan J; Witmer MR; Xie D; Hanumegowda U; Knipe J; Mosure K; Santone KS; Parker DD; Zhuo X; Lemm J; Liu M; Pelosi L; Rigat K; Voss S; Wang Y; Wang YK; Colonno RJ; Gao M; Roberts SB; Gao Q; Ng A; Meanwell NA; Kadow JF
    J Med Chem; 2014 Mar; 57(5):1855-79. PubMed ID: 24397558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemical genetics-based discovery of indole derivatives as HCV NS5B polymerase inhibitors.
    Jin G; Lee S; Choi M; Son S; Kim GW; Oh JW; Lee C; Lee K
    Eur J Med Chem; 2014 Mar; 75():413-25. PubMed ID: 24561671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and initial optimization of alkoxyanthranilic acid derivatives as inhibitors of HCV NS5B polymerase.
    Parcella K; Nickel A; Beno BR; Sheriff S; Wan C; Wang YK; Roberts SB; Meanwell NA; Kadow JF
    Bioorg Med Chem Lett; 2017 Jan; 27(2):295-298. PubMed ID: 27908764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conformation-based restrictions and scaffold replacements in the design of hepatitis C virus polymerase inhibitors: discovery of deleobuvir (BI 207127).
    LaPlante SR; Bös M; Brochu C; Chabot C; Coulombe R; Gillard JR; Jakalian A; Poirier M; Rancourt J; Stammers T; Thavonekham B; Beaulieu PL; Kukolj G; Tsantrizos YS
    J Med Chem; 2014 Mar; 57(5):1845-54. PubMed ID: 24159919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.